Linear B Exchange

Linear B Exchange, Powered by BDI Pharma, Inc. (the nation’s fastest growing national distributor of specialty pharmaceuticals), has set its sights on evolving the next generation supply chain strategies, focusing on a true cost-per-unit, alternative distribution model. The pharmaceutical industry faces increasing challenges based on the complexities of modern healthcare. One of the primary challenges that BDI Pharma has the ability to address is the cost of distribution; namely, paying more fees to continue to fund a model that is close to unsustainable. Utilizing Linear B Exchange, an exclusive distribution model, BDI provides a distinctive solution. The focus being on orphan drugs and specialty pharmaceuticals with unique molecules, BDI looks to bring best-in-class practices to the supply chain with the ultimate goal of evolving pharmaceutical distribution towards a cost-per-unit model. Not all drugs are designed to fit within the Linear B Exchange model, so BDI continues to seek out additional manufacturers with the right types of drug that will thrive in an alternative distribution environment. Bringing a cost-per-unit model to manufacturers also offers benefits as it relates to CMS regulations.